Published in J Neurosci on August 26, 2009
Soluble amyloid beta-protein dimers isolated from Alzheimer cortex directly induce Tau hyperphosphorylation and neuritic degeneration. Proc Natl Acad Sci U S A (2011) 3.11
Anti-tau antibodies that block tau aggregate seeding in vitro markedly decrease pathology and improve cognition in vivo. Neuron (2013) 3.09
Tau mislocalization to dendritic spines mediates synaptic dysfunction independently of neurodegeneration. Neuron (2010) 2.68
In vivo microdialysis reveals age-dependent decrease of brain interstitial fluid tau levels in P301S human tau transgenic mice. J Neurosci (2011) 2.00
Immunotherapy targeting pathological tau prevents cognitive decline in a new tangle mouse model. J Neurosci (2010) 1.97
Identification of oligomers at early stages of tau aggregation in Alzheimer's disease. FASEB J (2012) 1.70
Pharmacologic Inhibition of 5-Lipoxygenase Improves Memory, Rescues Synaptic Dysfunction, and Ameliorates Tau Pathology in a Transgenic Model of Tauopathy. Biol Psychiatry (2015) 1.46
Increased 4R-Tau Induces Pathological Changes in a Human-Tau Mouse Model. Neuron (2016) 1.42
Targeting phospho-Ser422 by active Tau Immunotherapy in the THYTau22 mouse model: a suitable therapeutic approach. Curr Alzheimer Res (2012) 1.41
Tau passive immunotherapy in mutant P301L mice: antibody affinity versus specificity. PLoS One (2013) 1.29
The role of microglia in synaptic stripping and synaptic degeneration: a revised perspective. ASN Neuro (2010) 1.26
Moderate traumatic brain injury causes acute dendritic and synaptic degeneration in the hippocampal dentate gyrus. PLoS One (2011) 1.23
Mouse models of Alzheimer's disease. Brain Res Bull (2011) 1.19
Why pleiotropic interventions are needed for Alzheimer's disease. Mol Neurobiol (2010) 1.18
c-Abl in neurodegenerative disease. J Mol Neurosci (2011) 1.15
Murine models of Alzheimer's disease and their use in developing immunotherapies. Biochim Biophys Acta (2010) 1.14
Changes in dendritic complexity and spine morphology in transgenic mice expressing human wild-type tau. Brain Struct Funct (2010) 1.13
The intersection of amyloid β and tau in glutamatergic synaptic dysfunction and collapse in Alzheimer's disease. Ageing Res Rev (2013) 1.05
Anti-inflammatory impact of minocycline in a mouse model of tauopathy. Front Psychiatry (2010) 1.03
Allosteric heat shock protein 70 inhibitors rapidly rescue synaptic plasticity deficits by reducing aberrant tau. Biol Psychiatry (2013) 1.03
Soluble forms of tau are toxic in Alzheimer's disease. Transl Neurosci (2012) 1.02
Lessons from tau-deficient mice. Int J Alzheimers Dis (2012) 1.01
Sensitive quantitative assays for tau and phospho-tau in transgenic mouse models. Neurobiol Aging (2012) 1.01
Synaptic alterations in the rTg4510 mouse model of tauopathy. J Comp Neurol (2013) 0.99
Curcumin suppresses soluble tau dimers and corrects molecular chaperone, synaptic, and behavioral deficits in aged human tau transgenic mice. J Biol Chem (2012) 0.99
Microarray analysis of CA1 pyramidal neurons in a mouse model of tauopathy reveals progressive synaptic dysfunction. Neurobiol Dis (2011) 0.97
Soluble pathological tau in the entorhinal cortex leads to presynaptic deficits in an early Alzheimer's disease model. Acta Neuropathol (2013) 0.96
Immunotherapy for tauopathies. J Mol Neurosci (2011) 0.92
Distinct Therapeutic Mechanisms of Tau Antibodies: Promoting Microglial Clearance Versus Blocking Neuronal Uptake. J Biol Chem (2015) 0.91
Cognitive and cortical plasticity deficits correlate with altered amyloid-β CSF levels in multiple sclerosis. Neuropsychopharmacology (2010) 0.90
Characterization of tau oligomeric seeds in progressive supranuclear palsy. Acta Neuropathol Commun (2014) 0.89
Anti-tau antibody reduces insoluble tau and decreases brain atrophy. Ann Clin Transl Neurol (2015) 0.89
Templated misfolding of Tau by prion-like seeding along neuronal connections impairs neuronal network function and associated behavioral outcomes in Tau transgenic mice. Acta Neuropathol (2015) 0.88
Tau Oligomers Derived from Traumatic Brain Injury Cause Cognitive Impairment and Accelerate Onset of Pathology in Htau Mice. J Neurotrauma (2016) 0.87
Extracellular Tau Oligomers Produce An Immediate Impairment of LTP and Memory. Sci Rep (2016) 0.86
The diarylheptanoid (+)-aR,11S-myricanol and two flavones from bayberry (Myrica cerifera) destabilize the microtubule-associated protein tau. J Nat Prod (2010) 0.86
The formation of tau pore-like structures is prevalent and cell specific: possible implications for the disease phenotypes. Acta Neuropathol Commun (2014) 0.85
From epidemiology to pathophysiology: what about caffeine in Alzheimer's disease? Biochem Soc Trans (2014) 0.85
Cytoplasmic retention of protein phosphatase 2A inhibitor 2 (I2PP2A) induces Alzheimer-like abnormal hyperphosphorylation of Tau. J Biol Chem (2014) 0.84
Chronic Repetitive Mild Traumatic Brain Injury Results in Reduced Cerebral Blood Flow, Axonal Injury, Gliosis, and Increased T-Tau and Tau Oligomers. J Neuropathol Exp Neurol (2016) 0.82
Sevoflurane induces tau phosphorylation and glycogen synthase kinase 3β activation in young mice. Anesthesiology (2014) 0.82
Natural products as a rich source of tau-targeting drugs for Alzheimer's disease. Future Med Chem (2012) 0.82
Rodent models for Alzheimer's disease drug discovery. Expert Opin Drug Discov (2015) 0.82
The role of tau in neurodegenerative diseases and its potential as a therapeutic target. Scientifica (Cairo) (2012) 0.82
Allergy influences the inflammatory status of the brain and enhances tau-phosphorylation. J Cell Mol Med (2012) 0.82
Transgenic models of Alzheimer's disease: better utilization of existing models through viral transgenesis. Biochim Biophys Acta (2013) 0.81
Tau Hyperphosphorylation and Oxidative Stress, a Critical Vicious Circle in Neurodegenerative Tauopathies? Oxid Med Cell Longev (2015) 0.80
Isolation and characterization of antibody fragments selective for toxic oligomeric tau. Neurobiol Aging (2014) 0.80
Cognitive and sensorimotor tasks for assessing functional impairments in mouse models of Alzheimer's disease and related disorders. Methods Mol Biol (2012) 0.80
Evidence that the presynaptic vesicle protein CSPalpha is a key player in synaptic degeneration and protection in Alzheimer's disease. Mol Brain (2015) 0.80
Human tau expression reduces adult neurogenesis in a mouse model of tauopathy. Neurobiol Aging (2015) 0.79
Motor-coordination-dependent learning, more than others, is impaired in transgenic mice expressing pseudorabies virus immediate-early protein IE180. PLoS One (2010) 0.79
Characterization of age-related changes in synaptic transmission onto F344 rat basal forebrain cholinergic neurons using a reduced synaptic preparation. J Neurophysiol (2013) 0.79
Specific serotonergic denervation affects tau pathology and cognition without altering senile plaques deposition in APP/PS1 mice. PLoS One (2013) 0.79
Tau Oligomers: The Toxic Player at Synapses in Alzheimer's Disease. Front Cell Neurosci (2015) 0.78
Spatial training preserves associative memory capacity with augmentation of dendrite ramification and spine generation in Tg2576 mice. Sci Rep (2015) 0.78
Effect of the inhaled anesthetics isoflurane, sevoflurane and desflurane on the neuropathogenesis of Alzheimer's disease (review). Mol Med Rep (2015) 0.78
Glucose deficit triggers tau pathology and synaptic dysfunction in a tauopathy mouse model. Transl Psychiatry (2017) 0.78
Impaired burrowing is the most prominent behavioral deficit of aging htau mice. Neuroscience (2016) 0.77
A systems approach to drug discovery in Alzheimer's disease. Neurotherapeutics (2015) 0.77
Tau-mediated synaptic damage in Alzheimer's disease. Transl Neurosci (2015) 0.77
Tau accumulation induces synaptic impairment and memory deficit by calcineurin-mediated inactivation of nuclear CaMKIV/CREB signaling. Proc Natl Acad Sci U S A (2016) 0.77
High copy wildtype human 1N4R tau expression promotes early pathological tauopathy accompanied by cognitive deficits without progressive neurofibrillary degeneration. Acta Neuropathol Commun (2015) 0.77
Reducing tau aggregates with anle138b delays disease progression in a mouse model of tauopathies. Acta Neuropathol (2015) 0.77
Increased dendritic spine density and tau expression are associated with individual differences in steroidal regulation of male sexual behavior. PLoS One (2013) 0.77
Silencing [Formula: see text] Rescues Tau Pathologies and Memory Deficits through Rescuing PP2A and Inhibiting GSK-3β Signaling in Human Tau Transgenic Mice. Front Aging Neurosci (2014) 0.77
Tau physiology and pathomechanisms in frontotemporal lobar degeneration. J Neurochem (2016) 0.76
Hyperphosphorylated tau causes reduced hippocampal CA1 excitability by relocating the axon initial segment. Acta Neuropathol (2017) 0.76
Humanized Tau Mice with Regionalized Amyloid Exhibit Behavioral Deficits but No Pathological Interaction. PLoS One (2016) 0.75
Intranasal BMP9 Ameliorates Alzheimer Disease-Like Pathology and Cognitive Deficits in APP/PS1 Transgenic Mice. Front Mol Neurosci (2017) 0.75
Selective suppression of the α isoform of p38 MAPK rescues late-stage tau pathology. Alzheimers Res Ther (2016) 0.75
Tau downregulates BDNF expression in animal and cellular models of Alzheimer's disease. Neurobiol Aging (2016) 0.75
Tau Oligomers Associate with Inflammation in the Brain and Retina of Tauopathy Mice and in Neurodegenerative Diseases. J Alzheimers Dis (2016) 0.75
Extracellular truncated tau causes early presynaptic dysfunction associated with Alzheimer's disease and other tauopathies. Oncotarget (2017) 0.75
Abolishing Tau cleavage by caspases at Aspartate(421) causes memory/synaptic plasticity deficits and pre-pathological Tau alterations. Transl Psychiatry (2017) 0.75
A synaptic model of memory: long-term potentiation in the hippocampus. Nature (1993) 29.13
Developments of a water-maze procedure for studying spatial learning in the rat. J Neurosci Methods (1984) 16.43
Association of missense and 5'-splice-site mutations in tau with the inherited dementia FTDP-17. Nature (1998) 15.24
The hippocampus as a spatial map. Preliminary evidence from unit activity in the freely-moving rat. Brain Res (1971) 15.17
Long-lasting potentiation of synaptic transmission in the dentate area of the anaesthetized rabbit following stimulation of the perforant path. J Physiol (1973) 14.99
Neurofibrillary tangles but not senile plaques parallel duration and severity of Alzheimer's disease. Neurology (1992) 9.30
A new one-trial test for neurobiological studies of memory in rats. 1: Behavioral data. Behav Brain Res (1988) 7.29
Selective impairment of learning and blockade of long-term potentiation by an N-methyl-D-aspartate receptor antagonist, AP5. Nature (1986) 7.10
The essential role of hippocampal CA1 NMDA receptor-dependent synaptic plasticity in spatial memory. Cell (1996) 6.96
Mutation in the tau gene in familial multiple system tauopathy with presenile dementia. Proc Natl Acad Sci U S A (1998) 6.13
Neurofibrillary tangles, amyotrophy and progressive motor disturbance in mice expressing mutant (P301L) tau protein. Nat Genet (2000) 6.12
Behavioral and functional analysis of mouse phenotype: SHIRPA, a proposed protocol for comprehensive phenotype assessment. Mamm Genome (1997) 4.15
Neurotrophins are required for nerve growth during development. Nat Neurosci (2001) 3.96
Hyperphosphorylation and aggregation of tau in mice expressing normal human tau isoforms. J Neurochem (2003) 3.79
Neurofibrillary tangles, amyloid, and memory in aging and mild cognitive impairment. Arch Neurol (2003) 3.47
Monoclonal antibody PHF-1 recognizes tau protein phosphorylated at serine residues 396 and 404. J Neurosci Res (1994) 3.26
Age-dependent neurofibrillary tangle formation, neuron loss, and memory impairment in a mouse model of human tauopathy (P301L). J Neurosci (2005) 3.20
Modulation of synaptic transmission and long-term potentiation: effects on paired pulse facilitation and EPSC variance in the CA1 region of the hippocampus. J Neurophysiol (1993) 3.07
Cell-cycle reentry and cell death in transgenic mice expressing nonmutant human tau isoforms. J Neurosci (2005) 2.94
Inhibition of neuronal maturation in primary hippocampal neurons from tau deficient mice. J Cell Sci (2001) 2.82
Double dissociation between the effects of peri-postrhinal cortex and hippocampal lesions on tests of object recognition and spatial memory: heterogeneity of function within the temporal lobe. J Neurosci (2004) 2.76
Hydrofluoric acid-treated tau PHF proteins display the same biochemical properties as normal tau. J Biol Chem (1992) 2.40
Facilitation, augmentation and potentiation at central synapses. Trends Neurosci (2000) 2.27
Expression of multiple tau isoforms and microtubule bundle formation in fibroblasts transfected with a single tau cDNA. J Cell Biol (1989) 2.24
Neuropathological staging of Alzheimer lesions and intellectual status in Alzheimer's and Parkinson's disease patients. Neurosci Lett (1993) 2.16
Defects in axonal elongation and neuronal migration in mice with disrupted tau and map1b genes. J Cell Biol (2000) 1.98
Characterization of pathology in transgenic mice over-expressing human genomic and cDNA tau transgenes. Neurobiol Dis (2000) 1.84
Overexpression of tau in a nonneuronal cell induces long cellular processes. J Cell Biol (1991) 1.77
Effects of frontotemporal dementia FTDP-17 mutations on heparin-induced assembly of tau filaments. FEBS Lett (1999) 1.53
Sense and antisense transfection analysis of tau function: tau influences net microtubule assembly, neurite outgrowth and neuritic stability. J Cell Sci (1994) 1.46
Multi-metric behavioral comparison of APPsw and P301L models for Alzheimer's disease: linkage of poorer cognitive performance to tau pathology in forebrain. Brain Res (2004) 1.18
A genomic sequence analysis of the mouse and human microtubule-associated protein tau. Mamm Genome (2001) 1.11
Tau is required for neurite outgrowth and growth cone motility of chick sensory neurons. Cell Motil Cytoskeleton (1999) 0.96
An immunohistochemical study of GABA A receptor gamma subunits in Alzheimer's disease hippocampus: relationship to neurofibrillary tangle progression. Neuropathology (2008) 0.94
Guidelines for the use and interpretation of assays for monitoring autophagy. Autophagy (2012) 20.08
TDP-43 immunoreactivity in hippocampal sclerosis and Alzheimer's disease. Ann Neurol (2007) 5.98
Axonopathy and transport deficits early in the pathogenesis of Alzheimer's disease. Science (2005) 5.49
Macroautophagy--a novel Beta-amyloid peptide-generating pathway activated in Alzheimer's disease. J Cell Biol (2005) 4.91
Trans-synaptic spread of tau pathology in vivo. PLoS One (2012) 4.53
RIM1alpha forms a protein scaffold for regulating neurotransmitter release at the active zone. Nature (2002) 4.37
Heterosynaptic LTD of hippocampal GABAergic synapses: a novel role of endocannabinoids in regulating excitability. Neuron (2003) 4.32
Loss of presenilin function causes impairments of memory and synaptic plasticity followed by age-dependent neurodegeneration. Neuron (2004) 4.21
Endocannabinoid-mediated synaptic plasticity in the CNS. Annu Rev Neurosci (2006) 3.95
Hyperphosphorylation and aggregation of tau in mice expressing normal human tau isoforms. J Neurochem (2003) 3.79
Correlation of Alzheimer disease neuropathologic changes with cognitive status: a review of the literature. J Neuropathol Exp Neurol (2012) 3.77
Fibrillar amyloid deposition leads to local synaptic abnormalities and breakage of neuronal branches. Nat Neurosci (2004) 3.59
Linking Abeta and tau in late-onset Alzheimer's disease: a dual pathway hypothesis. Neuron (2008) 3.08
Inhibition of glycogen synthase kinase-3 by lithium correlates with reduced tauopathy and degeneration in vivo. Proc Natl Acad Sci U S A (2005) 2.95
Cell-cycle reentry and cell death in transgenic mice expressing nonmutant human tau isoforms. J Neurosci (2005) 2.94
Double-knockout mice for alpha- and beta-synucleins: effect on synaptic functions. Proc Natl Acad Sci U S A (2004) 2.62
A polymorphism in CALHM1 influences Ca2+ homeostasis, Abeta levels, and Alzheimer's disease risk. Cell (2008) 2.55
Endocannabinoid-mediated metaplasticity in the hippocampus. Neuron (2004) 2.50
Endocannabinoid signaling and long-term synaptic plasticity. Annu Rev Physiol (2009) 2.35
Protein kinase A regulates calcium permeability of NMDA receptors. Nat Neurosci (2006) 2.34
Resveratrol promotes clearance of Alzheimer's disease amyloid-beta peptides. J Biol Chem (2005) 2.31
AMP-activated protein kinase signaling activation by resveratrol modulates amyloid-beta peptide metabolism. J Biol Chem (2010) 2.21
Colocalization of tau and alpha-synuclein epitopes in Lewy bodies. J Neuropathol Exp Neurol (2003) 2.20
Neuropathologic features of frontotemporal lobar degeneration with ubiquitin-positive inclusions with progranulin gene (PGRN) mutations. J Neuropathol Exp Neurol (2007) 2.19
Cdk5 is a key factor in tau aggregation and tangle formation in vivo. Neuron (2003) 2.17
A polymorphic gene nested within an intron of the tau gene: implications for Alzheimer's disease. Proc Natl Acad Sci U S A (2002) 2.14
Retromer deficiency observed in Alzheimer's disease causes hippocampal dysfunction, neurodegeneration, and Abeta accumulation. Proc Natl Acad Sci U S A (2008) 2.09
CALHM1 ion channel mediates purinergic neurotransmission of sweet, bitter and umami tastes. Nature (2013) 2.08
Measurement of phosphorylated tau epitopes in the differential diagnosis of Alzheimer disease: a comparative cerebrospinal fluid study. Arch Gen Psychiatry (2004) 2.07
TRPV1 activation by endogenous anandamide triggers postsynaptic long-term depression in dentate gyrus. Nat Neurosci (2010) 2.06
Distinct functions of kainate receptors in the brain are determined by the auxiliary subunit Neto1. Nat Neurosci (2011) 2.00
Performance-based measures of everyday function in mild cognitive impairment. Am J Psychiatry (2010) 1.96
Utility of combinations of biomarkers, cognitive markers, and risk factors to predict conversion from mild cognitive impairment to Alzheimer disease in patients in the Alzheimer's disease neuroimaging initiative. Arch Gen Psychiatry (2011) 1.94
Guidelines for the prevention and management of Mycobacterium tuberculosis infection and disease in adult patients with chronic kidney disease. Thorax (2010) 1.91
Passive immunization with anti-Tau antibodies in two transgenic models: reduction of Tau pathology and delay of disease progression. J Biol Chem (2011) 1.91
Novel therapeutic approach for the treatment of Alzheimer's disease by peripheral administration of agents with an affinity to beta-amyloid. J Neurosci (2003) 1.88
αβγ-Synuclein triple knockout mice reveal age-dependent neuronal dysfunction. Proc Natl Acad Sci U S A (2010) 1.83
Long-term potentiation selectively expressed by NMDA receptors at hippocampal mossy fiber synapses. Neuron (2008) 1.83
Passive immunization targeting pathological phospho-tau protein in a mouse model reduces functional decline and clears tau aggregates from the brain. J Neurochem (2011) 1.82
Concepts for risk-based surveillance in the field of veterinary medicine and veterinary public health: review of current approaches. BMC Health Serv Res (2006) 1.81
Endocannabinoid-mediated long-term plasticity requires cAMP/PKA signaling and RIM1alpha. Neuron (2007) 1.81
Assessing the role of Ih channels in synaptic transmission and mossy fiber LTP. Proc Natl Acad Sci U S A (2002) 1.81
A technique for serial collection of cerebrospinal fluid from the cisterna magna in mouse. J Vis Exp (2008) 1.80
Small misfolded Tau species are internalized via bulk endocytosis and anterogradely and retrogradely transported in neurons. J Biol Chem (2012) 1.79
The beleaguered consultation. Br J Gen Pract (2006) 1.77
Dense-core plaques in Tg2576 and PSAPP mouse models of Alzheimer's disease are centered on vessel walls. Am J Pathol (2005) 1.77
Correlation of cerebrospinal fluid levels of tau protein phosphorylated at threonine 231 with rates of hippocampal atrophy in Alzheimer disease. Arch Neurol (2005) 1.75
Alzheimer disease-specific conformation of hyperphosphorylated paired helical filament-Tau is polyubiquitinated through Lys-48, Lys-11, and Lys-6 ubiquitin conjugation. J Biol Chem (2006) 1.68
The familial dementia BRI2 gene binds the Alzheimer gene amyloid-beta precursor protein and inhibits amyloid-beta production. J Biol Chem (2005) 1.67
Axonal transport rates in vivo are unaffected by tau deletion or overexpression in mice. J Neurosci (2008) 1.65
Should the practice of medicine be a deontological or utilitarian enterprise? J Med Ethics (2011) 1.62
Traditional markers of excessive alcohol use. Addiction (2003) 1.62
Rab3B protein is required for long-term depression of hippocampal inhibitory synapses and for normal reversal learning. Proc Natl Acad Sci U S A (2011) 1.60
Transcriptional regulation of beta-secretase by p25/cdk5 leads to enhanced amyloidogenic processing. Neuron (2008) 1.59
Patients and the new contracts. BMJ (2003) 1.59
The phospholipase D1 pathway modulates macroautophagy. Nat Commun (2010) 1.56
Gold for the NHS. What exactly is being bought with this gold? BMJ (2002) 1.55
Redundant functions of RIM1alpha and RIM2alpha in Ca(2+)-triggered neurotransmitter release. EMBO J (2006) 1.53
New directions for frontotemporal dementia drug discovery. Alzheimers Dement (2007) 1.53
Blockade of calcium-permeable AMPA receptors protects hippocampal neurons against global ischemia-induced death. Proc Natl Acad Sci U S A (2005) 1.53
Control and elimination of porcine reproductive and respiratory syndrome virus. Virus Res (2010) 1.52
A single in-vivo exposure to delta 9THC blocks endocannabinoid-mediated synaptic plasticity. Nat Neurosci (2004) 1.46
Semantic distance abnormalities in mild cognitive impairment: their nature and relationship to function. Am J Psychiatry (2012) 1.43
Tuberculosis in the UK--time to regain control. BMJ (2011) 1.43
Differential diagnosis of Alzheimer disease with cerebrospinal fluid levels of tau protein phosphorylated at threonine 231. Arch Neurol (2002) 1.41
Religious slaughter. Vet Rec (2003) 1.39
The non-principal phenomenon: a threat to continuity of care and patient enablement? Br J Gen Pract (2004) 1.38
Piccolo and bassoon maintain synaptic vesicle clustering without directly participating in vesicle exocytosis. Proc Natl Acad Sci U S A (2010) 1.38
MRI assessment of neuropathology in a transgenic mouse model of Alzheimer's disease. Magn Reson Med (2004) 1.37
Presenilin mutations in familial Alzheimer disease and transgenic mouse models accelerate neuronal lysosomal pathology. J Neuropathol Exp Neurol (2004) 1.36
Presenilin redistribution associated with aberrant cholesterol transport enhances beta-amyloid production in vivo. J Neurosci (2003) 1.36
Detection of Alzheimer's amyloid in transgenic mice using magnetic resonance microimaging. Magn Reson Med (2003) 1.35
Contrasting pathology of the stress granule proteins TIA-1 and G3BP in tauopathies. J Neurosci (2012) 1.34
Tau passive immunotherapy in mutant P301L mice: antibody affinity versus specificity. PLoS One (2013) 1.29
RIM1alpha phosphorylation at serine-413 by protein kinase A is not required for presynaptic long-term plasticity or learning. Proc Natl Acad Sci U S A (2008) 1.28
Interneuron activity controls endocannabinoid-mediated presynaptic plasticity through calcineurin. Proc Natl Acad Sci U S A (2008) 1.27
Synaptic plasticity of NMDA receptors: mechanisms and functional implications. Curr Opin Neurobiol (2012) 1.27
Tau phosphorylated at tyrosine 394 is found in Alzheimer's disease tangles and can be a product of the Abl-related kinase, Arg. J Alzheimers Dis (2010) 1.26
An immunohistochemical study of cases of sporadic and inherited frontotemporal lobar degeneration using 3R- and 4R-specific tau monoclonal antibodies. Acta Neuropathol (2006) 1.24
Dopaminergic modulation of endocannabinoid-mediated plasticity at GABAergic synapses in the prefrontal cortex. J Neurosci (2010) 1.24
Novel synthetic small-molecule activators of AMPK as enhancers of autophagy and amyloid-β peptide degradation. FASEB J (2010) 1.24
Deregulation of cdk5, hyperphosphorylation, and cytoskeletal pathology in the Niemann-Pick type C murine model. J Neurosci (2002) 1.24
Cholesterol in Alzheimer's disease and tauopathy. Ann N Y Acad Sci (2002) 1.23
ELKS2alpha/CAST deletion selectively increases neurotransmitter release at inhibitory synapses. Neuron (2009) 1.23
Chronic neuropathological and neurobehavioral changes in a repetitive mild traumatic brain injury model. Ann Neurol (2014) 1.23
AMPK is abnormally activated in tangle- and pre-tangle-bearing neurons in Alzheimer's disease and other tauopathies. Acta Neuropathol (2010) 1.22
Discovering discovery patterns with Predication-based Semantic Indexing. J Biomed Inform (2012) 1.22
RIM1alpha and RIM1beta are synthesized from distinct promoters of the RIM1 gene to mediate differential but overlapping synaptic functions. J Neurosci (2008) 1.21
Collapsin response mediator protein-2 hyperphosphorylation is an early event in Alzheimer's disease progression. J Neurochem (2007) 1.20
Statin therapy for Alzheimer's disease: will it work? J Mol Neurosci (2002) 1.19
Visualization of beta-amyloid plaques in a transgenic mouse model of Alzheimer's disease using MR microscopy without contrast reagents. Magn Reson Med (2004) 1.19
Therapeutic potential of resveratrol in Alzheimer's disease. BMC Neurosci (2008) 1.19
REST-dependent epigenetic remodeling promotes the developmental switch in synaptic NMDA receptors. Nat Neurosci (2012) 1.17